Pacer Advisors
OLMA icon

Pacer Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Pacer Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-580
Closed -$6.28K – 2652
2024
Q2 		$6.28K Sell
580
-789
-58% -$8.56K ﹤0.01% 3616
2024
Q1 		$15.5K Buy
+1,369
New +$17.7K ﹤0.01% 3483

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Pacer Advisors's OLMA Position: Q3 2024 in Review

Pacer Advisors sold out of Olema Pharmaceuticals (OLMA) in Q3 2024, closing a stake of 580 shares — an estimated $6.28K sold.

Pacer Advisors first reported a position in OLMA in Q1 2024 and held it in 2 quarters. The position peaked at $15.5K in Q1 2024. 130 funds tracked by Wall St. Rank hold OLMA as of Q3 2024.

  • Pacer Advisors reported no remaining Olema Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 580 Olema Pharmaceuticals shares in Q3 2024, an estimated $6.28K.
  • Pacer Advisors first reported a position in Olema Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Olema Pharmaceuticals position peaked at $15.5K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.